GIST: overview and recent advances in treatment with imatinib mesylate
Intended for healthcare professionals
Clinical Previous     Next

GIST: overview and recent advances in treatment with imatinib mesylate

Anne McTiernan Clinical research associate in bone and soft tissue sarcomas, The Meyerstein Institute of Oncology, The Middlesex Hospital, London

The treatment of advanced and metastatic gastrointestinal stromal tumours (GIST) has been revolutionised by the development of the drug imatinib mesylate (Glivec), one of the first targeted molecular therapies available for the treatment of cancer. However, little has been previously documented about this rare tumour. The aim of this article is to provide an overview of GIST and its treatment, and discuss the nursing management of GIST patients. This is particularly timely given that the National Institute for Clinical Excellence is expected to publish its guidance for the use of Glivec in the treatment of unresectable and/or metastatic GISTs this September.

Cancer Nursing Practice. 3, 6, 28-32. doi: 10.7748/cnp2004.07.3.6.28.c7573

Your organisation does not have access to this article
Recommend to your librarian
RCNi-Plus
Already have access? Log in

OR

3-month trial offer for �5.25/month

Subscribe today and save 50% on your first three months
RCNi Plus users have full access to the following benefits:
  • Unlimited access to all 10 RCNi Journals
  • RCNi Learning featuring over 175 modules to easily earn CPD time
  • NMC-compliant RCNi Revalidation Portfolio to stay on track with your progress
  • Personalised newsletters tailored to your interests
  • A customisable dashboard with over 200 topics
Subscribe

Alternatively, you can purchase access to this article for the next seven days. Buy now


Are you a student? Our student subscription has content especially for you.
Find out more